NSE: LUPIN · 6 October 2026
- Lupin Limited shares moved higher during the trading session, gaining 0.91% to trade at ₹2029.30 compared to its previous close of ₹2011.00. The stock opened at ₹2014.90 and moved within a day's range of ₹2004.20 and ₹2031.00.
- Lupin announced the launch of Formoflo-G® MDI, described as the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease management in India. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate as a twice-daily single-strength therapy following approval from the Drug Controller General of India. The rollout aims to target the large patient population suffering from COPD in India, where Lupin holds a strong ranking in the respiratory therapy segment.
- Trading volume was 1.62 times the 20-day average daily volume.
Why is LUPIN share price rising on 6 October 2026?
Lupin Limited shares moved higher during the trading session, gaining 0.91% to trade at ₹2029.30 compared to its previous close of ₹2011.00. The stock opened at ₹2014.90 and moved within a day's range of ₹2004.20 and ₹2031.00.
The broader market and sector benchmarks exhibited positive momentum during the session. The Nifty index rose by 0.98%, while the Nifty Pharma sector benchmark advanced 1.66%, indicating a supportive industry-wide backdrop that aligns with the day's upward price action.
Company disclosures from earlier in the month provide fundamental context for investor sentiment. Lupin recently announced the commercial launch of Formoflo-G® MDI in India, recognized as the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease management following approval from the Drug Controller General of India. While this business update adds to the company's established leadership in the domestic respiratory therapy segment, where it ranks second according to IQVIA data, the session's price movement reflects general market and sector participation alongside ongoing portfolio developments.
10.62 lakh shares traded by 6 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 6.54 lakh shares (1.62 times). The five-day average daily volume was 7.91 lakh shares. Separately, the NSE report for 5 October 2026 showed 3.23 lakh shares delivered, representing 56.47% of that day’s traded volume. The same report recorded 30,478 trades.
The stock's 0.91% advance occurred alongside positive broader market conditions and a strong 1.66% gain in the Nifty Pharma sector. Higher trading volume at 1.62 times the 20-day average and solid delivery participation of 56.47% provided underlying support, coinciding with recent product launch announcements.
Latest Company Developments
Lupin announced the launch of Formoflo-G® MDI, described as the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease management in India. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate as a twice-daily single-strength therapy following approval from the Drug Controller General of India. The rollout aims to target the large patient population suffering from COPD in India, where Lupin holds a strong ranking in the respiratory therapy segment.
It strengthens the company's respiratory product portfolio in the domestic market and reinforces its commercial execution in specialized chronic therapies.
The company announced that Multicare Pharmaceuticals Philippines, Inc., a subsidiary of its Dutch subsidiary Nanomi B.V., completed the buyback of 30,559 shares. Following this transaction, Multicare has become a wholly owned subsidiary of Nanomi and a step-down wholly owned subsidiary of Lupin Limited effective October 01, 2026.
It consolidates ownership structure within the group's international operating entities.
Lupin announced that it received tentative approval from the United States Food and Drug Administration for its New Drug Application for Apixaban Oral Suspension 1.25 mg/mL via the 505(b)(2) pathway. The oral liquid formulation serves as an alternative administration option for adult patients requiring anticoagulation therapy who have difficulty swallowing tablets. Upon final approval, the product will be manufactured at the company's Somerset, New Jersey facility.
It expands the company's differentiated product pipeline in the regulated U.S. market, supporting long-term growth visibility.
a press release dated October 06, 2026, titled "Lupin Launches Formoflo-G® MDI, World s First Fixed-dose Triple Combination Drug for COPD Management".
a press release dated August 06, 2026, titled "Lupin Q1 FY2027 Results ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.84% on 30 June 2026. This compares with 16.93% on 31 March 2026, a change of -2.09 percentage points.
The filing reported 39 MF/UTI holders.
Historical Bulk / Block Deals
Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com
What to Watch Next
- Execution and market uptake of the newly launched Formoflo-G MDI in the Indian respiratory segment
- Further regulatory updates regarding the U.S. FDA review for Apixaban Oral Suspension
- Delivery volume trends relative to the 20-day average of 1.62x to gauge sustained institutional participation
- Overall performance of the Nifty Pharma sector benchmark
More LUPIN news and dated analysis →
Frequently Asked Questions
What is the latest LUPIN company news?
Lupin announced the launch of Formoflo-G® MDI, described as the world's first fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease management in India. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate as a twice-daily single-strength therapy following approval from the Drug Controller General of India. The rollout aims to target the large patient population suffering from COPD in India, where Lupin holds a strong ranking in the respiratory therapy segment.
How strong was LUPIN’s trading volume?
10.62 lakh shares traded, 1.62 times the 20-day average daily volume. The price and volume data are dated 6 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Article by: WittyTrades Research Desk
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.